Brief: Eyepoint Announces Strategic Prioritization
BRIEF-Eyepoint Announces Strategic Prioritization Oct 19 (Reuters) - EyePoint Inc EYPT.O:
EYEPOINT ANNOUNCES STRATEGIC PRIORITIZATION
EYEPOINT - ANNOUNCES STRATEGIC PRIORITIZATION TO FOCUS ON DURAVYU IN DME
EYEPOINT - BOARD APPROVES PLAN TO REDUCE WORKFORCE BY ABOUT 53% AND END PHASE 3 WET AMD TRIALS EARLY
EYEPOINT - TO PRIORITIZE DURAVYU FOR DME WITH PHASE 3 DATA EXPECTED Q4 2027
EYEPOINT - STRATEGIC PRIORITIZATION EXPECTED TO GENERATE ANNUALIZED SAVINGS OF ABOUT $30 MILLION
EYEPOINT - ESTIMATES AGGREGATE CHARGES OF ABOUT $9 MILLION FOR EMPLOYEE SEPARATION BENEFITS
EYEPOINT - WORKFORCE REDUCTION OF ABOUT 53% TO OCCUR Q4 2026 AND COMPLETE H1 2027
Source text: ID:nGNXc3KySj
Further company coverage: EYPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on EyePoint
See all newsUS RESEARCH ROUNDUP-Axon Enterprise, Williams-Sonoma, Xcel Energy
US STOCKS ON THE MOVE-CoreWeave, Moderna, Datadog
U.S. STOCKS ON THE MOVE-Amazon, CoreWeave, Moderna
U.S. STOCKS ON THE MOVE-Centrus Energy, Disc Medicine, Crypto
EyePoint to halve workforce after experimental drug fails second late-stage trial (updated)